MicroRNA-1826 directly targets beta-catenin (CTNNB1) and MEK1 (MAP2K1) in VHL-inactivated renal cancer

Carcinogenesis

Volumn 33, Issue 3, 2012, Pages 501-508

  Hirata, Hiroshi ^a   Hinoda, Yuji ^b   Ueno, Koji ^a   Nakajima, Koichi ^c   Ishii, Nobuhisa ^c   Dahiya, Rajvir ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; LUCIFERASE; MICRORNA; MICRORNA 1826; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; MALE; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 84857979406     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr302     Document Type: Article

References (29)

1. Jemal,A. et al.(2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
2. Bukowski,R.M. (1997) Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer, 80, 1198-1220.
3. Linehan,W.M. et al.(2010) Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med., 61, 329-343.
4. Walsh,N. et al.(2009) Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol., 9, 6.
5. Pirrotta,M.T. et al.(2011) Targeted-therapy in advanced renal cell carcinoma. Curr. Med. Chem., 18, 1651-1657.
6. Linehan,W.M. et al.(2009) VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. Int. J. Biochem. Cell Biol., 41, 753-756.
7. Linehan,W.M. et al.(2007) Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res., 15, 671s-679s.
8. Peruzzi,B. et al.(2006) The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl Acad. Sci. USA, 103, 14531-14536.
9. Conrad,P.W. et al.(1999) EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J. Biol. Chem., 274, 33709-33713.
10. Trang,P. et al.(2008) MicroRNAs as potential cancer therapeutics. Oncogene, 27, S52-S57.
11. Inui,M. et al.(2010) MicroRNA control of signal transduction. Nat. Rev. Mol. Cell Biol., 11, 252-263.
12. Wang,X. (2008) miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA, 14, 1012-1017.
13. Kohno,M. et al.(2006) Targeting the ERK signaling pathway in cancer therapy. Ann. Med., 38, 200-211.
14. Yacoub,A. et al.(2006) MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biol. Ther., 5, 1332-1339.
15. Hirata,H. et al.(2011) DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma. Cancer, 117, 1649-1660.
16. Barker,N. et al.(2006) Mining the Wnt pathway for cancer therapeutics. Nat. Rev. Drug Discov., 5, 997-1014.
17. Yamaguchi,T. et al.(2011) Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol., 39, 23-31.
18. Costa,L.J. et al.(2007) Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells. Urology, 69, 596-602.
19. Eulitt,P.J. et al.(2011) Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery. Cancer Biol. Ther., 10, 1290-1305.
20. Xia,H. et al.(2010) miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem. Biophys. Res. Commun., 391, 535-541.
21. Saydam,O. et al.(2009) Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol. Cell. Biol., 29, 5923-5940.
22. Ichimura,A. et al.(2010) MicroRNA-34a inhibits cell proliferation by repressing mitogen-activated protein kinase kinase 1 during megakaryocytic differentiation of K562 cells. Mol. Pharmacol., 77, 1016-1024.
23. Nakashima,T. et al.(2010) Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PLoS One, 5, e14334.
24. Bilim,V. et al.(2000) Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations. Clin. Cancer Res., 6, 460-466.
25. Parker,A.S. et al.(2006) High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma. Cancer, 107, 37-45.
26. Crispen,P.L. et al.(2008) Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer, 113, 450-460.
27. Wang,G.C. et al.(2009) Expression of cortactin and survivin in renal cell carcinoma associated with tumor aggressiveness. World J. Urol., 27, 557-563.
28. Sato,A. et al.(2006) Survivin associates with cell proliferation in renal cancer cells: regulation of survivin expression by insulin-like growth factor-1, interferon-gamma and a novel NF-kappaB inhibitor. Int. J. Oncol., 28, 841-846.
29. Griffith,T.S. et al.(2002) Induction and regulation of tumor necrosis factorrelated apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res., 62, 3093-3099.